Published in AIDS on January 14, 2011
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res (2012) 1.33
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09
Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr (2014) 0.91
Microbicides: still a long road to success. Trends Microbiol (2012) 0.90
Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. J Infect Dis (2015) 0.87
Incidence of herpes simplex virus type 2 infections in Africa: a systematic review. Open Forum Infect Dis (2014) 0.87
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. J Infect Dis (2015) 0.84
Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health (2012) 0.81
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. Med Microbiol Immunol (2014) 0.80
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev (2016) 0.80
Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. Clin Med Insights Womens Health (2014) 0.79
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis (2017) 0.75
HSV-2 acquisition among HIV-1 infected adults treated with tenofovir as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study. J Infect Dis (2017) 0.75
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA (2003) 8.76
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77
HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS (2008) 2.67
Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med (2011) 2.48
Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS One (2007) 2.44
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol (2010) 2.10
Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS (2002) 1.92
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS One (2009) 1.87
Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood (2011) 1.85
Illness in intensive care staff after brief exposure to severe acute respiratory syndrome. Emerg Infect Dis (2003) 1.76
Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol (2011) 1.67
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS (2009) 1.64
Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. AIDS (2009) 1.63
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol (2010) 1.60
Structures of three HIV-1 HLA-B*5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J Immunol (2005) 1.60
Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J Infect Dis (2005) 1.58
Recombination following superinfection by HIV-1. AIDS (2004) 1.57
Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.55
Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 1.55
Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J Infect Dis (2008) 1.53
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS (2010) 1.47
Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS (2007) 1.47
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr (2002) 1.45
Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS (2004) 1.38
Associations of sexual risk taking among Kenyan female sex workers after enrollment in an HIV-1 prevention trial. J Acquir Immune Defic Syndr (2005) 1.37
Reduced rates of HIV acquisition during unprotected sex by Kenyan female sex workers predating population declines in HIV prevalence. AIDS (2008) 1.36
HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One (2009) 1.35
Quality and quantity: mucosal CD4+ T cells and HIV susceptibility. Curr Opin HIV AIDS (2012) 1.29
Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ (2003) 1.25
Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS (2011) 1.22
Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol (2008) 1.22
Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS (2009) 1.21
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis (2006) 1.20
Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med (2010) 1.19
Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol (2013) 1.18
Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol (2006) 1.17
Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr (2008) 1.16
Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis (2013) 1.15
High HIV risk in a cohort of male sex workers from Nairobi, Kenya. Sex Transm Infect (2013) 1.15
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol (2005) 1.12
Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis (2008) 1.11
Sustained changes in sexual behavior by female sex workers after completion of a randomized HIV prevention trial. J Acquir Immune Defic Syndr (2007) 1.10
Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection. J Immunol (2006) 1.09
HIV-specific CD8+ lymphocytes in semen are not associated with reduced HIV shedding. J Immunol (2005) 1.09
Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (2005) 1.08
Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One (2012) 1.07
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr (2010) 1.05
Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses (2009) 1.03
Genital immunology and HIV susceptibility in young women. Am J Reprod Immunol (2012) 1.02
A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis (2013) 0.99
Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada. AIDS Patient Care STDS (2008) 0.99
Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev (2008) 0.99
One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med (2007) 0.96
Gender and ethnicity differences in HIV-related stigma experienced by people living with HIV in Ontario, Canada. PLoS One (2012) 0.96
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials (2011) 0.96
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 0.96
Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. PLoS One (2012) 0.96
The effect of an education program on violence in the emergency department. Ann Emerg Med (2002) 0.95
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000-2009. BMC Infect Dis (2013) 0.94
Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol (2008) 0.93
Vitamin D association with estradiol and progesterone in young women. Cancer Causes Control (2010) 0.93
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther (2004) 0.92
Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis (2011) 0.92
Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals. Antivir Ther (2014) 0.92
HIV infection deregulates innate immunity to malaria despite combination antiretroviral therapy. AIDS (2013) 0.91
Feasibility and safety of cervical biopsy sampling for mucosal immune studies in female sex workers from Nairobi, Kenya. PLoS One (2012) 0.91
HIV infection deregulates Tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration. J Acquir Immune Defic Syndr (2013) 0.90
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS (2007) 0.90
Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin. AIDS (2012) 0.89
Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis (2009) 0.88
HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS One (2008) 0.88
HLA typing in a Kenyan cohort identifies novel class I alleles that restrict cytotoxic T-cell responses to local HIV-1 clades. AIDS (2002) 0.88
Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS (2008) 0.87
Neisseria gonorrhoeae effectively blocks HIV-1 replication by eliciting a potent TLR9-dependent interferon-α response from plasmacytoid dendritic cells. Cell Microbiol (2010) 0.87
HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res (2008) 0.87
Stay it with flora: maintaining vaginal health as a possible avenue for prevention of human immunodeficiency virus acquisition. J Infect Dis (2008) 0.87
Vaccines in the public eye. Nat Med (2005) 0.87
Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One (2010) 0.87
Treatment of HIV infection in pregnant women: antiretroviral management options. Drugs (2004) 0.86
Enumeration of sex workers in the central business district of Nairobi, Kenya. PLoS One (2013) 0.86
Stable CD4 expression and local immune activation in the ectocervical mucosa of HIV-infected women. J Immunol (2013) 0.86
No difference in keratin thickness between inner and outer foreskins from elective male circumcisions in Rakai, Uganda. PLoS One (2012) 0.85
Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV? Can J Infect Dis Med Microbiol (2009) 0.85